Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.47 |
| ▸ | G6PD | P11413 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7461220 | 0.88 | NR4A2 (0.47) | NR4A2SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL1132599 | 0.86 | G6PD (0.54) | NR4A2SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL7531657 | 0.85 | NR4A2 (0.59) | NR4A2SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL7459668 | 0.84 | NR4A2 (0.47) | NR4A2SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL13757430 | 0.83 | NR4A2 (0.53) | NR4A2SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL13763605 | 0.83 | NR4A2 (0.53) | NR4A2SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL11129174 | 0.82 | NR4A2 (0.61) | NR4A2SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL13757501 | 0.81 | NR4A2 (0.51) | NR4A2SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL7458613 | 0.81 | NR4A2 (0.54) | NR4A2SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL14871760 | 0.80 | HTR1A (0.53) | SLC40A1HTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-7767818-B2 | Hepatitis C inhibitor dipeptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7511157-B2 | racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1114033-B1 | 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6395751-B1 | SYNERGISTIC MIXTURE; ANTICHOLESTEROL AGENTS | PFIZER INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1114033-A1 | 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | Pfizer Products Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| US-6147090-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS USED TO TREAT DISEASES WHICH ARE EXACERBATED BY LOW LEVELS OF HDL CHOLESTEROL AND/OR HIGH LEVELS OF LDL-CHOLESTEROL AND TRIGLYCERIDES, SUCH AS ATHEROSCLEROSIS AND CARDIOVASCULAR | PFIZER INC. (US) | 2000-11-14 | — | — | US | disclosed |
| WO-2000017166-A1 | 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | DPP3, CTSC, ANPEP | NR4A2 1614/4885SMN1; SMN2 4344/4885KDM4E 3511/4885 |
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | NR4A2 3771/4885SMN1; SMN2 1564/4885KDM4E 2496/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NR4A2 3771/4885SMN1; SMN2 1564/4885KDM4E 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.